Positions

Selected Publications

Academic Article

Year Title Altmetric
2023 Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma.  Cancers.  15:1816. 2023
2022 Skewed fate and hematopoiesis of CD34+ HSPCs in umbilical cord blood amid the COVID-19 pandemic.  iScience.  25. 2022
2022 Efficient derivation of chimeric-antigen receptor-modified TSCM cells.  Frontiers in Immunology.  13. 2022
2022 CCR5 closes the temporal window for memory linking.  Nature.  606:146-152. 2022
2021 Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.  Journal for ImmunoTherapy of Cancer.  9. 2021
2020 Abstract 5655: Efficacy of antibodies targeting TfR1 in xenograft mouse models of AIDS-related non-Hodgkin lymphoma.  Cancer Research.  80:5655-5655. 2020
2020 Membrane-proximal external region is a superior target for mediating effector activity of HIV-1 specific chimeric antigen receptor modified T cells 2020
2020 Enhanced Delivery of Rituximab Into Brain and Lymph Nodes Using Timed-Release Nanocapsules in Non-Human Primates.  Frontiers in Immunology.  10. 2020
2019 Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice.  Nature Biomedical Engineering.  3:706-716. 2019
2019 Volumetric fluorescein angiography (vFA) by oblique scanning laser ophthalmoscopy in mouse retina at 200 B-scans per second..  Biomedical Optics Express.  10:4907-4918. 2019
2019 A Bioinspired Platform for Effective Delivery of Protein Therapeutics to the Central Nervous System.  Advanced Materials.  31. 2019
2019 Drug Delivery: A Bioinspired Platform for Effective Delivery of Protein Therapeutics to the Central Nervous System (Adv. Mater. 18/2019).  Advanced Materials.  31:1970127. 2019
2018 Modeling Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1 2018
2017 Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS.  PLoS Pathogens.  13:e1006753. 2017
2017 Purging Exhausted Virus-Specific CD8 T Cell Phenotypes by Somatic Cell Reprogramming.  AIDS Research and Human Retroviruses.  33:S59-S69. 2017
2016 Stem-cell based engineered immunity against HIV infection in the humanized mouse model.  Journal of Visualized Experiments.  2016. 2016
2016 A shared neural ensemble links distinct contextual memories encoded close in time.  Nature.  534:115-118. 2016
2016 Specific elimination of latently HIV-1 infected cells using HIV-1 protease-sensitive toxin nanocapsules.  PLoS One.  11. 2016
2015 HIV-specific Immunity Derived from Chimeric Antigen Receptor-engineered Stem Cells.  Molecular Therapy.  23:1358-1367. 2015
2015 Ectopic expression of anti-HIV-1 shRNAs protects CD8+ T cells modified with CD4ζ CAR from HIV-1 infection and alleviates impairment of cell proliferation.  Biochemical and Biophysical Research Communications.  463:216-221. 2015
2015 Modulation of gene expression by polymer nanocapsule delivery of DNA cassettes encoding small RNAs.  PLoS One.  10. 2015
2014 CREB regulates memory allocation in the insular cortex.  Current Biology.  24:2833-2837. 2014
2014 Deep sequencing reveals low incidence of endogenous LINE-1 retrotransposition in human induced pluripotent stem cells.  PLoS One.  9. 2014
2014 High-throughput screening of effective siRNAs using luciferase-linked chimeric mRNA.  PLoS One.  9. 2014
2013 C-Met-Dependent Multipotent Labyrinth Trophoblast Progenitors Establish Placental Exchange Interface.  Developmental Cell.  27:373-386. 2013
2012 Engineering HIV-1-Resistant T-Cells from Short-Hairpin RNA-Expressing Hematopoietic Stem/Progenitor Cells in Humanized BLT Mice.  PLoS One.  7. 2012
2010 Generation of human induced pluripotent stem cells bearing an anti-HIV transgene by a lentiviral vector carrying an internal murine leukemia virus promoter.  Human gene therapy. Clinical development.  21:1556-1567. 2010
2010 Live cell monitoring of hiPSC generation and differentiation using differential expression of endogenous microRNAs.  PLoS One.  5. 2010
2010 Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction.  Journal of Gene Medicine.  12:255-265. 2010
2009 Targeted transduction via CD4 by a lentiviral vector uses a clathrin-mediated entry pathway.  Journal of Virology.  83:13026-13031. 2009
2009 Virion-associated Vpr of human immunodeficiency virus type 1 triggers activation of apoptotic events and enhances fas-induced apoptosis in human t cells.  Journal of Virology.  83:11283-11297. 2009
2009 Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5.  Genetic Vaccines and Therapy.  7. 2009
2009 Enhanced transthyretin tetramer stability following expression of an amyloid disease transsuppressor variant in mammalian cells.  Journal of Gene Medicine.  11:103-111. 2009
2009 Regulation of Prostate-Specific Antigen Expression by the Junctional Adhesion Molecule A.  Urology.  73:1119-1125. 2009
2009 Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells.  PLoS Pathogens.  5. 2009
2008 Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for Cdc2.  Journal of Virology.  82:5672-5682. 2008
2007 Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates 2007
2007 Novel nuclear import of Vpr promoted by importin a is crucial for human immunodeficiency virus type 1 replication in macrophages.  Journal of Virology.  81:5284-5293. 2007
2007 Human immunodeficiency virus type 1 Vpr interacts with spliceosomal protein SAP145 to mediate cellular pre-mRNA splicing inhibition 2007
2006 Corrigendum to "Cell-based chemical genetic screen identifies damnacanthal as an inhibitor of HIV-1 Vpr induced cell death" [Biochem. Biophys. Res. Commun. 348 (2006) 1101-1106] (DOI:10.1016/j.bbrc.2006.07.158).  Biochemical and Biophysical Research Communications.  351:791. 2006
2006 Cell-based chemical genetic screen identifies damnacanthal as an inhibitor of HIV-1 Vpr induced cell death.  Biochemical and Biophysical Research Communications.  348:1101-1106. 2006
2005 A novel role for Vpr of human immunodeficiency virus type 1 as a regulator of the splicing of cellular pre-mRNA 2005
2005 Importin-α promotes passage through the nuclear pore complex of human immunodeficiency virus type 1 Vpr.  Journal of Virology.  79:3557-3564. 2005
2004 Nuclear localization of Vpr is crucial for the efficient replication of HIV-1 in primary CD4 + T cells.  Virology.  327:249-261. 2004
2004 Increased levels of Wee-1 kinase in G2 are necessary for Vpr- and gamma irradiation-induced G2 arrest.  Journal of Virology.  78:8183-8190. 2004
2001 T cell apoptosis causes peripheral T cell depletion in mice transgenic for the HIV-1 vpr gene.  Virology.  285:181-192. 2001
2000 Induction of apoptosis by the Vpr protein of human immunodeficiency virus type 1 occurs independently of G2 arrest of the cell cycle.  Virology.  276:16-26. 2000
2000 Two putative α-helical domains of human immunodeficiency virus type 1 Vpr mediate nuclear localization by at least two mechanisms.  Journal of Virology.  74:7179-7186. 2000
2000 A carboxy-terminally truncated form of the human immunodeficiency virus type 1 Vpr protein induces apoptosis via G1 cell cycle arrest.  Journal of Virology.  74:6058-6067. 2000
2000 Dynamic distribution of an antigen involved in the differentiation of avian myoblasts: II. Possible association of β1 integrin with myofibril organization.  Cytoskeleton.  45:27-41. 2000
1999 A carboxy-terminally truncated form of the Vpr protein of human immunodeficiency virus type 1 retards cell proliferation independently of G2 arrest of the cell cycle.  Virology.  263:313-322. 1999
1997 Human immunodeficiency virus type 1 Vpr gene product prevents cell proliferation on mouse NIH3T3 cells without the G2 arrest of the cell cycle.  Biochemical and Biophysical Research Communications.  232:550-554. 1997
1994 Effect of Ca2+ on Morphogenesis of HVJ (Sendai virus) Virion in LLC-MK2 cells: Suppression of Viral Production.  Cell Structure and Function.  19:315-323. 1994
1994 Further Analysis of The Effect of Ca2+ on Morphogenesis of HVJ (Sendai Virus) in LLC-MK2 Cells: Effects on Phosphorylated M Protein Associated with Viral Morphogenesis.  Cell Structure and Function.  19:325-333. 1994

Research Overview

  • The major research foci of our laboratory are understanding a) how viruses or malignant cells establish and maintain prolonged infections or uncontrolled cell division, respectively, in patients under host immune pressure and b) how the host immune system can be mobilized to fight infection or cancer. To this end, we have worked to establish effective strategies using humanized mouse and non-human primate models; our aim is to develop a treatment capable of achieving a state wherein the host immune system decreases levels of virus or cancer in patients to the point where further treatment is not necessary.
    Our recent efforts using immunotherapeutic strategies have provided potential tools for controlling HIV-1 load as well as aggressive cancers that metastasize to the brain. These studies provide fundamental insight into the basis of host-virus and host-malignant cell interactions and ultimately identify clinically relevant therapeutic targets to augment immune responses and restore antiviral or anticancer immunity in patients.

    • Principal Investigator On

    Investigator On

    Education And Training

  • Doctor of Philosophy in Pharmaceutical Sciences, Kyoto Pharmaceutical University 1995
  • Bachelor of Pharmacy in Pharmaceutical Sciences, Kyoto Pharmaceutical University 1990

    • Full Name

  • Masakazu Kamata